Nachrichten zur Merck & Co. Inc. Aktie

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Mercks Keytruda.…

Newsblog zum Unternehmen: Siemens baut Partnerschaft mit Merck aus

Siemens und der Pharmakonzern intensivieren ihre Zusammenarbeit im Bereich der modularen Produktion. +++ Alles Entwicklungen zu Siemens im Newsblog. +++…

Merck’s Top-Seller Cements Status in Hard-to-Treat Breast Cancer

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the…

Merck Appears Ready To Return To June Highs (Technical Analysis)

…

Moderna cites 2025 launch for Merck partnered cancer vaccine: report

…

Top Biotech, With 85% Gain This Week, Rockets Again On Sale

The company is adding onto its success outperforming Mercks top drug in lung cancer patients.…

Merck: Es läuft wie geschmiert - Explosionsartige Umsatzzuwächse aber nicht erwartet - Aktienanalyse

Wien (www.aktiencheck.de) - Merck-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), erhöht das…

Merck Aktie: Innovatives ADC-Reaktor stärkt Marktposition

Merck, ein führendes Wissenschafts- und Technologieunternehmen, hat den ersten skalierbaren Einweg-Mischer speziell für die Herstellung von Antikörper-Wirkstoff-Konjugaten (ADCs) auf den…

Summit Hits Record High on Lung Cancer Drug Topping Mercks Keytruda

Data from a late-stage study shows that SMMTs experimental antibody beat Keytruda in a head-to-head setting in treating certain patients…

MRK Stock Dips After SMMTs Cancer Drug Outshines Keytruda in Study

Mercks Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase…

Apples iPhone 16 launch, Mattel CEO: Market Domination

Its that time of day again, the final trading hour of Monday, September 9. Market Domination hosts Julie Hyman and…

Why Summit Therapeutics Rocketed Over 60% Today

The companys new lung cancer treatment could unseat Mercks Keytruda in the $50 billion-plus lung cancer treatment market.…

Why Summit Therapeutics Rocketed Over 60% Today @themotleyfool #stocks $SMMT $MRK

The companys new lung cancer treatment could unseat Mercks Keytruda in the $50 billion-plus lung cancer treatment market.…

Top Stock Movers Now: Boeing, Palantir Technologies, Merck, Alphabet, and More

U.S. equities rallied back from last weeks selloff at midday as investors put more money into blue chip stocks.…

Stocks making the biggest premarket moves: Boeing, Dell, Merck and more

These are the stocks posting the largest moves in the premarket.…

Merck, Daiichi post mid-stage data for novel lung cancer drug

…

Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

…

Kurs der Merck KGaA-Aktie verharrt auf Vortags-Niveau (170,25 €)

Am deutschen Aktienmarkt ist die Aktie von Merck gegenwärtig unauffällig. Der jüngste Kurs betrug 170,25 Euro. Die Wertschätzung der Börsenteilnehmer…

Global Hematologic Malignancies Market Size To Worth USD 144.58 Billion By 2033 | CAGR Of 7.97%

The Global Hematologic Malignancies Market Size was Valued at USD 67.18 Billion in 2023 and the Worldwide Hematologic Malignancies Market…

Pharma Stock Roundup: EU Nod for Expanded Use of MRKs Keytruda & More

European Commission approves expanded use of Mercks Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies…

Merck (MRK) Stock Moves -0.63%: What You Should Know

Merck (MRK) closed the most recent trading day at $117.84, moving -0.63% from the previous trading session.…

Whats Wrong With Mercks Stock?

Is the healthcare stock an underrated buy right now?…

Whats Wrong With Mercks Stock? @themotleyfool #stocks $MRK

Is the healthcare stock an underrated buy right now?…

Mercks Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma

MRKs Keytruda gets approval in combination with Astellas and Pfizers Padcev for treating first-line advanced urothelial carcinoma.…

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Data from an early-stage study shows that PCVXs pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and…

Updating Walmart, Merck And Nike Post-Earnings

…

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a…

Mercks Change To Profit Guidance Provides An Opportunity

…

Best-performing Small-cap Biotech Stocks on the ASX in 2024

The global biotechnology sector is on track to become a multi-trillion dollar industry. Worldwide, the biotech space is worth an…

Merck scraps two late-stage trials of cancer drug Keytruda

Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company…

MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate

Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a…

Merck Stock Worth Watching on PAH Drug Winrevairs Approval in Europe?

MRKs Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.…

Merck, Bristol Myers cancer drugs included in September FDA advisory panel meeting

…

Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?

Declining estimates and the recent price drop make investors skeptical about holding Mercks (MRK) stock.…

Top Analyst Reports for Costco, Merck & Linde

Todays Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), Merck & Co., Inc.…

Merck Aktie: Kurssteigerung und Prognosen

Aktuelle Kursentwicklung Am heutigen Handelstag legte die Merck-Aktie im XETRA-Handel ab 15:53 Uhr um 0,6 Prozent zu und notierte bei…

Merck & Co: Eine Reihe von Herausforderungen und Chancen - Aktienanalyse

Wien (www.aktiencheck.de) - Merck & Co-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI),…

Kurs der Merck, inc-Aktie verharrt auf Vortags-Niveau (102,7406 €)

Der Kurs der dem Anteilsschein von Merck, inc kommt kaum von der Stelle. Zuletzt zahlten Investoren für das Papier 113,14…

Pharma Stock Roundup: AZN Gets Approvals for Imfinzi Expanded Use, MRK Inks New Deal

Merck (MRK) signs a new collaboration with a private drugmaker. AstraZeneca (AZN) gets approvals for expanded use of Imfinzi.…

Mercks Weakness Could Mean Profits With This Bearish Option Trade

Merck stock is down 11% in the last three months and could potentially be headed for new lows.…

Merck: Buy This Bargain Before Its Gone

…

Merck: 205 oder 180 Euro? Alle Kursziele und Ratings nach Q2-Zahlen auf einen Blick - Aktiennews

Darmstadt (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Merck-Aktie (ISIN: DE0006599905, WKN:…

Merck (MRK) to Buy Curons Bispecific Antibody Drug for $1.3B

Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is…

Investing in Merck (NYSE:MRK) three years ago would have delivered you a 63% gain

While Merck & Co., Inc. ( NYSE:MRK ) shareholders are probably generally happy, the stock hasnt had particularly good...…

Aktie von Merck, inc: Kurs nur geringfügig im Minus (103,7226 €)

CODE Das Wertpapier notiert derzeit bei 113,29 US-Dollar. Die Wertschätzung der privaten und institutionellen Anlegern für die Aktie von Merck,…

JPMorgan belässt Merck KGaA auf Overweight - Ziel 190 Euro

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA nach Zahlen für das zweite Quartal…

Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRKs New Deal & Other Updates

Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner…

Merck Aktie: Ergebnisse beeinflussen Analystenprognosen

Die Merck & Co., Inc. bereitet sich auf die Veröffentlichung ihrer Q3 2024 Ergebnisse am 31. Oktober vor. Analysten erwarten…

Global Mother and Child Healthcare Market Size To Worth USD 2106.78 Billion by 2033 | CAGR of 11.28%

The Global Mother and Child Healthcare Market Size was Valued at USD 723.67 Billion in 2023 and the Worldwide Global…

Analyst Report: Merck & Co Inc

…